Cardiac Resynchronization Therapy (CRT) Market

Market Overview

The global Cardiac Resynchronization Therapy (CRT) Market was valued at approximately USD 5.1 billion in 2024 and is projected to reach USD 8.2 billion by 2033, growing at a CAGR of 5.5% during the forecast period (2025–2033).

Cardiac Resynchronization Therapy (CRT) consists of two special implantable devices (CRT-Pacemakers [CRT-P] and CRT-Defibrillators [CRT-D]) designed to improve or correct the rhythm and performance of the heart, especially in individuals with heart failure and electrical conduction abnormalities. CRT devices work by providing direct electrical stimulation to both the left and right ventricles; thus helping the heart perform more efficiently and with lower heart failure symptoms.

The CRT market’s growth is being driven by several factors, including an increasing incidence of heart failure, an aging population, and technology developments in the area of implantable cardiac devices. CRT outcomes are improving for patients providing a better reimburseable narrative, and the increasing awareness of treatment options for those with heart failure.

The arrival of MRI-compatible devices beginning to roll out flow through to remote monitoring in healthcare systems has furthered support in uptake of devices and CRT through developed, and emerging, healthcare systems.

Market Dynamics

Market Drivers 

Rising Prevalence of Heart Failure and Aging Population

The upward trend of heart failure occurrence in larger global populations, particularly among the older population, drives the CRT market. Heart failure is often due to a history of high blood pressure, coronary artery disease, and/or previous acute myocardial infarctions that create compromised or impaired cardiac functioning.

Cardiac resynchronization therapy (CRT), which can be done through implanted pacemakers or implantable cardioverter defibrillators, allows a patient whose heart has impaired motion to return to prescribed coordinated heartbeats, as well as to help improve their symptoms and increase their quality of life with a longer period of survival. According to the American Heart Association (2024), over 6.7 million Americans currently live with heart failure, which is projected to increase 46% by 2030.

Globally, heart failure affects over 64 million people. Natural declines in heart function and comorbidities among this age group also put the older population at greater risk with more severe forms of heart failure. Furthermore, the United Nations (2020) estimates that the global population of people over the age of 60 will reach 2.1 billion by 2050 – double the population of people over the age of 60 in 2020.

There will continue to be demand for CRT implants for the treatment and management of heart failure, especially in developed regions like North America, Japan, and Europe. More patients will be diagnosed earlier in the clinical trajectory of their heart failure population cycle. Because clinical practice guidelines involve the implementation of CRT with patients across the entire clinical care spectrum, device-based therapy will begin to play a larger role in global long-term management as developed regions continue to treat heart failure patients.

Technological Advancements and Remote Monitoring Integration

Technological advances in CRT technology are accelerating the market at a fast rate. Next-generation device innovations include longer-lasting batteries, smaller size, MRI compatibilities, plus new and advanced features such as Bluetooth-enabled remote monitoring. These advancements allow real-time cardiac function tracking, timely indicators of decompensation, better patient compliance and lesser rates of hospital visits.

For example, Medtronic recently launched the Cobalt™ XT CRT-D system in April of 2024, which has wireless connectivity and arrhythmia detection algorithms, while Boston Scientific’s Resonate™ CRT devices include HeartLogic™, a multi-sensor platform that predicts heart failure events before symptoms emerge. These innovations enhance therapeutic effectiveness and improve the concept of physician preference based on previous advancements with CRT.

Moreover, significant regulatory support and favorable reimbursement frameworks (especially in the US and EU) will fast track their adoption. Remote patient monitoring is also consistent with a worldwide transition toward value-based care and chronic disease management. Increased financing by many governments into digital health infrastructure will further aid transition toward increasing remote monitoring toward CRT devices.

As the World Economic Forum reported, health expenditures reached over $9.8 trillion as of 2021 and has only continued to increase. These latest advancements will make CRT more accessible, efficacious, and critical for incorporating CRT strategies for heart failure management.

Market Restraints

High Cost of CRT Devices and Limited Access in Low- and Middle-Income Countries

One of the main barriers to the development of the cardiac resynchronization therapy (CRT) market has been the cost of device implantation and follow-up care. CRT devices, in particular CRT-D (with defibrillator), are much more expensive than routine pacemakers or medical therapy, and while the device costs vary, the total treatment costs (including hospital costs, operating surgeon fees, and follow-up care) often bog each patient down over USD 30,000–50,000 (Mardini, 2018).

Cost is a limiting factor for utilization in low and middle-income countries (LMICs) since CRT patients often face heavily constrained healthcare budgets and reimbursement coverage is non-existent or marginal at best. Further, advanced CRT devices that incorporate remote monitoring functionality require unavailable digital infrastructure and specialist staff time. Even in the predominant developed markets, access to CRT may also be impeded by strict eligibility criteria, long prior authorization processes, and differences in insurance coverage.

According to the World Bank, over 50% of the global population do not have access to essential health care services (World Bank, n.d.). In access limited regions around the world are barriers to economic and logistical access to CRT treatments that ultimately limit uptake and slows broader global acceptance of CRT within the treatment of heart failure as standard care.

Segmental Analysis

The Cardiac Resynchronization Therapy (CRT) Market is segmented by product type and end-user. Each segment plays a crucial role in improving cardiac function and reducing hospitalizations in heart failure patients.

By Product Type

CRT-Defibrillators (CRT-D) had the biggest market share in 2024 due to their ability to offer two advances in one device – synchronized pacing therapy and defibrillation,​ in order to prevent sudden cardiac death. In addition, CRT-D are preferred in high-risk patients who have advanced heart failure and have a history of ventricular arrhythmias.

CRT-D are been increasingly adopted as clinical guidelines have become more positive about their use, and cardiologists now have a greater awareness of their advantages when compared to stand-alone pacemakers. CRT-Pacemakers (CRT-P) will have modest growth, especially, in the elderly or those patients who are contraindicated for defibrillator therapy.

The CRT-P also works well with resynchronization in patients that are less symptomatic of heart failure and had less arrhythmic risk. In addition, technological advances in CRT-P devices, such as size, battery longevity, and MRI compatibility have furthered their adoption in select patient populations.

By End-User

Hospitals take the largest segment of the CRT market in 2024. Hospitals provide the most CRT implants, and have an advanced cardiac care infrastructure, seasoned electrophysiologists, and comprehensive postoperative follow-up systems. Cardiac Centers are also growing quickly, benefitting from their complex heart failure training and advanced cardiac device-based therapy.

The strongly integrated care pathway and specialty nature of care locations create opportunities for them to ramp up CRT procedures. Ambulatory Surgical Centers (ASCs) are a low-cost option for potentially appropriate CRT patients, especially in developed countries with improvements in minimally invasive techniques and abbreviated recovery times.

ASCs have begun to offer CRT implantations for low-risk patients. ‘Other’ includes specialty clinics and academics and only holds a marginal share of the market, but is important for training, research, and early adoption of next-generation CRT devices.

Regional Analysis

North America

In terms of regional markets, North America will represent the largest share of the CRT market in 2024 at 38.5%. This is attributed to its established and high-volume healthcare system, high incidence of heart failure cases, and increasing adoption of implantable cardiac devices.

The U.S. is the largest contributor to North America due to its established network of hospitals and cardiac centers where CRT is implemented. Various factors are in place to support the continued growth of these markets, including an increase in patient awareness, favorable reimbursement policies, and continued technological innovation.

Europe

Europe will represent the second largest share of the CRT market at approximately 28.2% in 2024. The U.K., Spain, Germany, Italy, and France are all large contributors to the CRT market attributed to the high burden of cardiovascular disease and aging population. The steady growth of the CRT market is anticipated to continue partly due to the growth of the older population receiving cardiac care and increasing availability of cardiac care facilities and healthcare funding.

The increasing adoption of remote monitoring technologies in CRT devices among European healthcare systems as well as the older population demographics will be factors contributing to CRT market growth.

Asia-Pacific

Asia Pacific is the fastest-growing region with a 2024 market share of 20.4% and a projected CAGR of over 8% during the forecast period. The region’s rapid urbanization, increasing expenditure on healthcare, increasing prevalence of heart failure, and growing healthcare infrastructure in some major markets including China, India, Japan, and South Korea are driving demand. Accessibility to advanced cardiac therapies and government initiatives to improve chronic disease management would be key enablers of future growth.

Latin America and Middle East & Africa

Latin America and Middle East and Africa represent approximately 13% of the global CRT market in 2024. The two regions are not displaying factors of growth beyond a moderate level, which includes expanding investments in healthcare infrastructure, and increasing awareness of cardiovascular disease, and public will to improve health.

However, a range of challenge factors including disparity in economic growth, limited access to advanced cardiac therapies, and limited reimbursement coverage limits market access. If access to healthcare improves, and the affordability of the devices improves, these regions may open further opportunities.

Recent Development

1. December 2024 –  People at Heart Rhythm Society meeting noted improvements in CRT-D battery life, as the transvenous CRT-D models recorded a median battery life (3,364 days) better than competitors (Medtronic, 2,378 days; Abbott, 2,527 days) . 
2. September 2024 –FDA broadened indication for pacing [Sonic] INGEVITY™+ pacing leads, allowing for conduction system pacing of the left bundle-branch area to facilitate CRT procedures.